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The Pan-Cancer Analysis of Whole Genomes (PCAWG) project generated a vast amount of
whole-genome cancer sequencing resource data. Here, as part of the ICGC/TCGA Pan-
Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole gen-
ome sequencing data from 2658 cancers across 38 tumor types, we provide a user’s guide to
the five publicly available online data exploration and visualization tools introduced in the
PCAWG marker paper. These tools are ICGC Data Portal, UCSC Xena, Chromothripsis
Explorer, Expression Atlas, and PCAWG-Scout. We detail use cases and analyses for each
tool, show how they incorporate outside resources from the larger genomics ecosystem, and
demonstrate how the tools can be used together to understand the biology of cancers more
deeply. Together, the tools enable researchers to query the complex genomic PCAWG data
dynamically and integrate external information, enabling and enhancing interpretation.
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The Pan-Cancer Analysis of Whole Genomes (PCAWG)Consortium aggregated whole-genome sequencing (WGS)data from 2658 cancers across 38 tumor types generated by
the International Cancer Genome Consortium (ICGC) and The
Cancer Genome Atlas (TCGA) projects. These sequencing data
were re-analyzed with standardized, high-accuracy pipelines to
align to the human genome (reference build hs37d5) and identify
germline variants and somatically acquired mutations, as descri-
bed in the PCAWG marker paper1. Here we provide a user guide
to five tools introduced in the PCAWG marker paper: The ICGC
Data Portal, UCSC Xena, Chromothripsis Explorer, Expression
Atlas, and PCAWG-Scout. Each of them was created or extended
to explore PCAWG data resources1. All of the tools aim to
streamline analysis and visualization by pre-loading the PCAWG
data so that users do not need to locate, curate, or manage the
data and by making the tools accessible through a web interface.
Each of these five tools also integrates other genomics datasets
and tools that provide context and insight for interpretation of
patterns in the PCAWG data helping this resource fully realize its
potential. Some of the datasets and tools integrated include the
UCSC Genome Browser2, Ensembl3, drug target compendia4,
COSMIC5, and even large and complementary sequencing efforts
such as GTEx6. Intuitive access to these additional tools and
datasets is provided either by showing their data side by side or by
providing context-dependent URL links.
The five resources in this paper each provide a different per-
spective and focus to the PCAWG data (Table 1). The ICGC Data
Portal serves as the main entry point for accessing all PCAWG data
and also enables exploration of PCAWG consensus simple somatic
mutations, including point mutations and small indels, each by their
frequencies, patterns of co-occurrence, mutual exclusivity, and
functional associations. UCSC Xena integrates diverse types of
genomic and phenotypic/clinical information at the sample level
across the large number of samples, enabling rapid examination of
patterns within and across data types. The Chromothripsis Explorer
visualizes genome-wide mutational patterns, with a focus on com-
plex genomic events, e.g., chromothripsis and kataegis. This is
achieved through interactive Circos plots for each tumor with dif-
ferent tracks that correspond to allele-specific copy number variants,
somatic structural variations, simple somatic mutations, indels, and
clinical information. The Expression Atlas focuses on RNA-seq data,
supporting queries in either a baseline context (e.g., finding genes
that are expressed in prostate adenocarcinoma samples) or in a
differential context (e.g., finding genes that are under- or over-
expressed in prostate adenocarcinomas compared to adjacent nor-
mal prostate samples). PCAWG-Scout allows users to run their own
analyses on-demand, including prediction of cancer-driver genes,
differential gene expression, recurrent structural variations, survival,
pathway enrichment, mutations as visualized on a protein structure,
mutational signatures, and possible recommended therapies (based
on the in-house PanDrugs resource; Supplementary Fig. 1). Each of
the five tools offers different visualizations and analyses of the
PCAWG data resource, each with its own strengths, and each
enabling different insights into the data. When employed together,
they provide the user with a deeper understanding of the cancer’s
biology (Fig. 1). More information about the tools can be found at
the PCAWG Landing Page (http://docs.icgc.org/pcawg).
Results
ICGC Data Portal and a use case. As a main entry point, the
ICGC Data Portal (https://dcc.icgc.org, Zhang7) provides an
intuitive graphical interface for browsing, searching, and
Table 1 Search, visualization, analysis/integration, and download functionalities provided by each of the PCAWG data resources.





Search by demographic data, specimen phenotype,
molecular subtype
Y Y Y
Search by genes and/or variants Y Y Y Y
Search by genomic coordinates Y Y
Visualize
Visualize multiple types of data together Y Y Y Y
Visualize coding variants Y Y Y Y
Visualize non-coding variants Y Y Y
Visualize structural variants Y Y Y
Visualize mutational signatures and predicted
drivers
Y
Visualize genome-wide profiles, including LOH, in
Circos plots
Y
Visualize tissue expression on a human figure Y
Visualize gene co-expression Y Y
Visualize pathways, therapeutic associations Y Y
Visualize summary of BAMs/VCFs Y
Analysis
Kaplan–Meier analysis with statistics Y Y Y
Gene set/pathway enrichment analysis Y Y Y
View non-identifiable analysis results of
protected data
Y Y Y Y
Discover differentially or co-expressed genes,
mutually exclusive genomic events
Y
Annotations from other resources Y Y Y Y
Download
Programmatic data download Y Y Y Y
Download BAMs, VCFs, primary files Y
Download secondary processed data Y Y Y Y
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visualizing PCAWG datasets (Fig. 1a). Uniformly aligned
sequencing BAM files and variant calling VCF files, although
physically residing in multiple repositories globally, can be cen-
trally searched via the ICGC Data portal (https://icgc.org/ZEA).
Users can readily find specific datasets of interest with a few
mouse clicks using various facet terms to narrow their search.
Other downstream analysis results generated by PCAWG work-
ing groups are available at https://dcc.icgc.org/releases/PCAWG.
Close to 23 million open access PCAWG consensus simple
somatic mutations have been annotated with consequences for
protein structure, affected pathways, targeting cancer drugs, gene
ontology terms, and clinical parameters. The portal’s Advanced
Search (https://icgc.org/ZzP) tool allows users to perform com-
plex queries, for example, to retrieve the most frequently mutated
targets of drugs in stage 2 liver cancers (https://icgc.org/ZHe).
Analytic tools, including access to a Jupyter Notebook sandbox
for advanced users, support exploration of potential associations
between molecular abnormalities and phenotypic observations
such as donor survival (https://dcc.icgc.org/analysis). The ICGC
Data Portal publicly displays non-identifiable, aggregated analysis
results from protected data.
The ICGC Data Portal is best for users who are seeking to
download PCAWG data for their own analyses. It also includes
the richest resources and functionality for users interested in
single-nucleotide variants (SNVs), including patterns of co-
occurrence, mutual exclusivity, and functional associations.
Figure 1a shows an example use case that demonstrates how
bioinformaticians and other tool creators can download results
from the portal and then run their own analyses or offer their
own visualizations of the data.
Online resources for PCAWG data visualization
a
Search and 
download > 70,000 
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UCSC Xena and a use case. UCSC Xena’s (https://pcawg.
xenahubs.net) adaptable visualizations, fast performance, and
flexible data format make the full power of the PCAWG resource
available to all researchers8. It displays data mapped to coding and
non-coding regions of the genome, including introns, promoters,
enhancers, and intergenic regions. Xena can display tens of
thousands of data points on thousands of samples, all within
seconds. The Xena Browser excels at integrating the diverse
datasets generated by the PCAWG Consortium using the Xena
Visual Spreadsheet, which enables users to view multiple types of
data side by side (Fig. 1b). In addition to the Visual Spreadsheet,
Xena offers survival analyses, the ability to compare and contrast
dynamically built subgroups, statistical tests such as analysis of
variance, and URLs to live visualizations for sharing with colla-
borators or others. Xena’s hub-browser architecture enables
users to view the protected consensus simple somatic mutations,
including non-coding mutations, by loading the dataset into a
user’s local private Xena hub (Fig. 2, Supplementary Fig. 2). The
Xena Browser seamlessly integrates data from multiple
hubs, allowing users who have access to the protected mutation
data to visualize it in conjunction with other PCAWG data
publicly available on the PCAWG Xena Hub (https://pcawg.
xenahubs.net).
UCSC Xena is best for integrating diverse PCAWG data types,
including simple mutations, gene expression levels, and gene
fusions, as well as less common types such as alternative splicing1
events, promoter usage, and mutational signature scores, all from
the same set of samples (Supplementary Note 1). It also provides
a mechanism for viewing protected non-coding SNVs either
separately or in conjunction with other PCAWG data. Figure 2
shows an example use case, exploring alterations in the TERT
gene. Both public data (structural variants (SVs)) and private data
(SNVs) on the TERT gene are shown. The data are integrated in
the browser, keeping private data protected. Even though the data
are distributed across multiple hubs with different access controls,
they appear to the user to come from a unified dataset, allowing
easy visualization and data integration. Figure 2 shows alterations
by SNV and alterations by larger structural variation that are
mutually exclusive. We also see that there are significant
differences in the type of alteration in different cancer types
(chi-square, one-sided, F= 426.2, p < 0.001).
Chromothripsis Explorer and a use case. Chromothripsis refers
to a mutational process characterized by massive de novo rear-
rangements that affect one or multiple chromosomes9. The
whole-genome dataset assembled by PCAWG permitted us to
characterize chromothripsis patterns on a large scale at single-
base resolution across >30 cancer types10. Although chromo-
thripsis is generally identified by statistical metrics11, visual
inspection still remains essential to dismiss false-positive cases
generated by other mechanisms of genome instability10,12. The
Chromothripsis Explorer (http://compbio.med.harvard.edu/
chromothripsis/) is an open source R Shiny application that
visualizes chromothripsis patterns detected using WGS data1,10.
The Chromothripsis Explorer provides tools for exploration of
chromothripsis frequencies and patterns across tumor types
(Fig. 3a). Specifically, it provides interactive Circos plots13 for
each tumor, allowing researchers to explore large-scale alterations
such as chromosome arm deletions and complex mutational
patterns such as chromothripsis and chromoplexy (Fig. 3b). Each
Circos plot is divided into seven tracks that display, from outer to
inner rings: (i) hg19 cytobands; (ii) inter-mutation distance and
location for pathogenic (i.e., non-synonymous, stop-gain, and
stop-loss) and nonpathogenic SNVs, as well as frame-shift and in-
frame indels; (iii) chromothripsis regions; (iv) total copy number;
(v) minor copy number profiles, defined as the least amplified
allele, to visualize loss of heterozygosity (LOH) regions; (vi) gene
annotation track, and (vii) structural variations displayed
according to read orientations at the breakpoints (duplication-
like SVs in blue, deletion-like SVs in orange, head-to-head
inversions in black, and tail-to-tail inversions in green). By
hovering over a Circos plot, the user can obtain information
about a mutation of interest at single-base resolution and also see
gene annotations and functional effect predictions. In addition to
the genomic data, clinical and histo-pathological information are
provided for all tumors in the form of customizable tables that
enable the user to map tumor identifiers across cancer projects
(e.g., TCGA to ICGC IDs; Fig. 3b).
The Chromothripsis Explorer is best for users who are looking
for a global picture of somatic alterations in a tumor (e.g., large-
scale aneuploidies or translocations). It also provides visualizations
of the point mutations, as well as small insertions and deletions, on
a genome-wide scale. A representative use case for Chromothripsis
Explorer is the exploration of complex rearrangements in one or
more human cancers, as shown in Fig. 3b for ColoRect-AdenoCA
tumor ICGC ID: DO9034. By selecting the chromosomes that
harbor massive rearrangements, in this case chromosomes 5, 8, 10,
11, and 19, the user can investigate the consequences of complex
rearrangements such as LOH across chromosome 8 and copy
number amplifications in multiple locations.
Fig. 1 Synergy of the five tools. Instructions for reproducing the results shown are in Supplementary Note 2. a To obtain PCAWG BAMs, VCFs, and
Analysis Working Group (AWG) files, the user selects the files desired, downloads a file manifest, and then downloads the actual data files (with
authorization if needed) using the ICGC download tool. UCSC Xena, Chromothripsis Explorer, Expression Atlas, and PCAWG-Scout have each downloaded
and processed the same primary analysis working group result files. b The UCSC Xena Visual Spreadsheet shows that the ERG fusion is present in 8 out of
18 PCAWG prostate adenocarcinoma samples (https://tinyurl.com/y78adbl5), as detected by the PCAWG RNA-seq and whole-genome sequencing data.
Each row corresponds to a sample. Columns, starting at the left, correspond to histology, ERG gene expression, and ERG fusion based on RNA-seq data. The
last three columns show structural variant calls using whole-genome DNA-seq data for ERG, TMPRSS2, and SLC45A3. c Chromothripsis Explorer provides
an in-depth genome-wide view of copy number alterations and structural variations identified in the eight tumors with ERG fusion listed in b. Detailed
information on total and minor copy number variations, as well as SVs, can be obtained by hovering over the elements within the Chromothripsis Explorer.
Circos plot visualizations for the other 7 donors are given in Supplementary Fig. 4. d The Expression Atlas shows a heatmap of genes (rows) and tissue or
disease type (columns). Here we show the expression of TMPRSS2 and SLC45A3 in healthy human tissue (top heatmap), as derived from our re-analysis of
the GTEx dataset. The bottom heatmap shows expression in PCAWG data (https://tinyurl.com/y9fefymf). The human figure, called an anatomogram,
shows the prostate tissue, highlighted in red. e PCAWG-Scout complements the above analysis by identifying recurrent mutational events in tumors
without ERG fusion (fusion= 0). On the left is a mutation exclusivity analysis run by PCAWG-Scout (FDR-corrected Fisher’s exact test), which identifies
FOXA1 (***p < 0.0005), SPOP (**p < 0.005), SYNE1 (*p < 0.05), as significantly associated with non-fusion tumors (https://tinyurl.com/qqudbkg). In the
3D protein structure of SPOP shown on the right, mutations are seen to cluster tightly around the region that overlaps with the interaction surface of PTEN.
The portion of PTEN that interacts with SPOP is shown in yellow, along with the SPOP structure. Red indicates recurrent mutations in SPOP, with a brighter
red indicating higher rate of recurrence.
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Expression Atlas and a use case. Expression Atlas (https://www.
ebi.ac.uk/gxa/experiments/E-MTAB-5200/, Petryszak14) is an
added-value database and web service that enables the user to
assess gene expression in different tissues, cell types, diseases, and
developmental stages. It collects, annotates, re-analyses, and dis-
plays gene, transcript, and protein expression data. It supports two
types of study design: baseline and differential. Baseline studies
involve quantitation of genes by tissue type, developmental stage,
cell line, cancer type, or other factors. Differential studies perform
expression comparisons between different samples, for example,
disease vs. healthy tissue (Fig. 4). In addition to the PCAWG
datasets, selected expression studies from archives such as
ArrayExpress, GEO (Gene Expression Omnibus) and ENA (Eur-
opean Nucleotide Archive) also underwent further curation and
processing. Data curation is semi-automated and involves identi-
fying the experimental factors, such as diseases or perturbations,
annotating metadata with Experimental Factor Ontology (EFO)
terms, and describing the experimental comparisons for further
processing. Currently, Expression Atlas provides results from
>3500 experiments that include about 120,000 assays from >60
different organisms. The datasets cover >100 cell types from the
Cell Ontology and >700 diseases represented in the EFO.
Expression Atlas includes differential studies on human
diseases in humans and animal models as well as large baseline
studies on human subjects or cell lines, including GTEx, CCLE,
ENCODE, BLUEPRINT, and HipSci. Analyses of bulk or single-
cell RNA-seq datasets are performed using our open source
pipeline iRAP15. Expression Atlas can be searched by gene, gene
set, or experimental condition (Fig. 4a). Gene, transcript, and
protein expression across different conditions are displayed
through heatmaps and boxplots (Fig. 4b). Annotation of datasets
with EFO terms enables nested searching across related tissues,
diseases, and other conditions modeled within EFO. For example,
a search for “cancer” will produce results for all different types of
cancer, including “leukemia.” PCAWG datasets can be viewed
and queried within their study pages or they can be viewed
alongside other studies within Expression Atlas, returned as
matches to gene or condition queries from the home page.
Expression Atlas is best for users who are interested in viewing
how PCAWG gene expression data compare with those from
other sources, especially normal tissues in GTEx. It also provides
the ability to see gene expression on an anatomical figure, making
it easy to visualize patterns of expression across the body. An
example use case in Fig. 4 shows a typical gene search, in this case
for gene SFTPA2, to identify in which tissues it is expressed and
under what conditions its expression changes. The results of the
query show high expression in lung tissue across different
baseline expression studies available through Expression Atlas.
Focusing on the PCAWG datasets, we see that expression is low
in lung cancers (adenocarcinoma and squamous cell carcinoma),
whereas it is highly expressed in the corresponding adjacent
normal tissues. It is also highly expressed in lung samples from
GTEx. Finally, through the panel of available differential studies
(bulk RNA-Seq or microarray), the user can confirm from
additional studies in Expression Atlas that SFTPA2 is down-
regulated in lung cancers.
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Fig. 2 UCSC Xena views of TERT across cancer types. a Visual spreadsheet view of TERT multi-omics data across PCAWG cancer types. Data from the
PCAWG public hub are under the green section, and protected data from the user’s local Xena hub are under the red section. The public and private
datasets are integrated in the browser, keeping the private data protected. Many of the cancer types show TERT alterations, either as simple somatic
mutations in the promoter region (as seen in the pileup highlighted in the red box) or as structural variants (as seen in the breakpoint pileup upstream of
TERT highlighted in the purple box). Only cancer types that have a TERT alteration are displayed (n= 718 samples). The last column, dynamically generated
in the browser, shows which samples have promoter mutations, which have structural variants, and which have none. No sample is observed to have both
promoter mutations and structural variants; hence, the two types of alterations are mutually exclusive. b Distribution of different types of TERT alterations
across cancer types, as shown in Xena chart view. Xena automatically runs the appropriate statistical test for every chart; in this case, Xena calculated that
the difference in distributions across cancer types is statistically significant.
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PCAWG-Scout and a use case. As opposed to offering only a
limited and predefined list of analyses, PCAWG-Scout (http://
pcawgscout.bsc.es/) offers a variety of on-demand analysis func-
tionalities. The analyses enable researchers to explore and
visualize the data, form a hypothesis, run the relevant analysis,
and immediately explore and visualize the results, giving rise to
an analysis loop that drives discovery. The analyses are performed
on data from the PCAWG main data release (available in the
ICGC data repository) and on results from the PCAWG working
groups. Results from the working groups include driver calls for
different cohorts and for individual samples, mutation clonality
assignments, and mutational signatures, all of which are inte-
grated into different sections of the PCAWG-Scout reports,
tables, and interactive visualization graphics. PCAWG-Scout
generates a set of visualizations and analyses, called a report, on
any number of cohorts, samples, or genes. Reports include
descriptions, statistics, plots, interactive three-dimensional (3D)
protein representations, and network graphs (Fig. 5). The reports
also offer additional, optional analyses, including enrichment
analysis of gene lists, driver predictions over cohorts, survival
analysis for lists of samples, and potential recommended
therapies for individual donors (Supplementary Fig. 3). PCAWG-
Scout uses a plugin approach that makes it easy for the user to
customize reports or perform new types of analyses. Data and
results are exported in interoperable formats to help integrate
PCAWG-Scout with other software packages.
PCAWG-Scout is best for users who are looking for a web
interface to run analyses on PCAWG data (e.g., differential gene
expression or gene set enrichment). It also offers 3D mutation
views for coding SNVs and INDELs. The potential to explore
PCAWG data in PCAWG-Scout is illustrated in Fig. 5, which
shows a network visualization tool that was configured from the
web interface with parameters gathered through analyses run
within the tool itself. The tool offers the user a bird’s eye view of
a number of important facets of the biology, in the case of Fig. 5,
of central nervous system tumors. For instance, IDH1, TP53,
and DDX3X stand out as genes in which mutations are more
damaging than expected. Plots such as these can help the user
identify patterns such as mutual exclusivity and clinical
prognosis, as well as highlight the ways in which gene function
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Fig. 3 Functionalities of the Chromothripsis Explorer. a Interactive bar plot for visualization of chromothripsis rates for selected cancer types. The left-
hand side panel shows variables used for detection of chromothripsis patterns (e.g., number of copy number oscillations; Cortés-Ciriano10). The user can
modify the values of those variables to explore chromothripsis rates as a function of stringency criteria. The right-hand panel shows additional
functionalities for exploring the relationship between purity and ploidy for tumors of selected cancer types. b Visualization of complex rearrangements
involving five chromosomes in a ColoRect-AdenoCA donor (ICGC ID: DO9034). The right-hand panel shows a zoomed view of chromosome 8 that
illustrates the tracks available in the Circos plots. From the outer to the inner ring, the tracks correspond to hg19 cytobands, SNVs (colored according to the
mutation type and distributed according to the inter-mutation distance), total copy number (over a blue background), minor copy number (LOH regions,
with a minor copy number equal to 0 depicted in red), gene track, and SVs. Further information about the tracks can be accessed by clicking on the blue
information circle located above the Circos plot.
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Synergy of the different tools. Combining the strengths of the
different tools can provide a deeper understanding of tumor
biology. That synergy is illustrated by considering a common
driver event in prostate cancer: fusion of the oncogene ERG16,17
(Fig. 1). Xena’s Visual Spreadsheet enables the user to look across
all 18 PCAWG prostate samples with both WGS and RNA-seq
data, showing that 8 of the samples harbor an ERG fusion. These
samples also show ERG overexpression (Fig. 1b). A view of the
PCAWG SV data shows that, across all samples, the fusion
breakpoints are located at the ERG transcription start site, leaving
the ERG-coding region intact and fusing it to the promoter region
of TMPRSS2 or SLC45A3 (Fig. 1b). In addition, the figure shows
that fusions detected by RNA-seq and WGS are not always
consistent; one fusion detected by a consensus of RNA-based
detectors is missed in the WGS calls, and the converse is also
seen. This example shows that an integrated visualization across
multiple data types and algorithms can provide a more accurate
picture of a genomic event.
The Chromothripsis Explorer adds a more in-depth view of the
CNV and SV alterations in the eight tumors with ERG fusions. It
shows that alterations in those eight tumors vary widely (Fig. 1c,
Supplementary Fig. 4). Whereas donors DO36372, DO36359,
DO36265, and DO36335 have quiescent genomes with few SVs,
DO36356 and DO36283 show more complex karyotypes. For
example, in DO38283, chromosome 21 harbors multiple SVs
that link it with chromosomes 2, 9, 13, and 21 (right). A closer
look at the intrachromosomal SVs in chromosome 21 (left)
reveals an oncogenic fusion generated by a deletion at
chr21:39,988,805–40,578,907.
The Expression Atlas adds the observation that expression
levels of TMPRSS2 and SLC45A3 vary across tissue and tumor
types but that both TMPRSS2 and SLC45A3 are highly expressed
in normal prostate tissues and prostate tumors, as shown in the
Expression Atlas Baseline Expression Widget (Fig. 1d). Combined
analysis of the PCAWG and GTEx datasets leads to the
hypothesis that a subset of prostate cancers, through genome
rearrangement, hijack the promoters of androgen-responsive
genes to increase ERG expression, resulting in an androgen-
dependent overexpression of ERG.
PCAWG-Scout adds further information by illuminating
genomic events in the prostate samples that do not show ERG
fusions. Although ERG fusions are frequent, 46% (89 out of 195)
of the PCAWG prostate tumors do not show them (Supplemen-
tary Fig. 5). In fact, we can see using PCAWG-Scout’s mutual
exclusivity analysis that simple mutations in FOXA1, SPOP, and
SYNE1 are significantly associated with non-fusion tumors
(Fig. 1e). Furthermore, in PCAWG-Scout’s 3D protein structure
view, the mutations in SPOP cluster tightly around the interaction
interface for PTEN (Fig. 1e), suggesting that those mutations may
lead to altered SPOP protein function.
The use case in this section highlights some of the strengths of
each individual tool and also demonstrates how the tools can be
used synergistically to gain a fuller understanding of a genomic
event, in this case ERG fusions in prostate cancer. In this example,
we started with UCSC Xena, but the user can start with any of the
five tools and then use others to investigate further.
Discussion
The data generated by the PCAWG consortium provide a valu-
able resource for understanding complex cancer biology. Here we
have described five tools that aim to put that resource into the
hands of all researchers and also incorporate outside genomic
data resources. Those tools, the ICGC Data Portal, UCSC Xena,
Chromothripsis Explorer, Expression Atlas, and PCAWG-Scout,
are all available at The PCAWG Data Portals and Visualization
Page (http://docs.icgc.org/pcawg). Visualization of patterns
within the PCAWG data is challenging because of the relatively
large number of whole genomes studied, the large size of each
dataset at the sequence level, and the difficulty of viewing all
intergenic and intronic regions explicitly at either the sequence or
Gene search for SFTPA2
SFTPA2 is highly expressed in lung tissue
SFTPA2 is downregulated in lung cancers in other
studies within Expression Atlas
SFTPA2 has lower expression value in lung cancer types





Fig. 4 Example of a gene search in Expression Atlas. a Searching for experiments in which SFTPA2 is expressed or differentially expressed. b Viewing
expression of SFTPA2 in different tissues and across all baseline experiments. SFTPA2 shows consistently high expression in the lung. c Looking for the
same gene in the PCAWG study using Expression Atlas. Expression is low in lung cancers (adenocarcinoma and squamous cell) but high in the
corresponding adjacent normal tissue samples. Expression in normal lung is also high in GTEx. d Finally, the downregulation of SFTPA2 is confirmed in
further differential assay studies of lung cancer presented in Expression Atlas.
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gene level. Those factors impose high-performance requirements
for interactive tools, especially those on the web. Adding to the
high-performance requirements is the challenge of visualizing the
wide array of data types derived from the high-quality genomic
information provided by whole-genome data, including point
mutations, gene fusions, promoter usage, and SVs. Many visua-
lization tools, especially those for users without extensive com-
putational training, are currently limited to coding regions and
more typical genomic datasets such as those on SNVs or CNVs;
they are not able to take full advantage of the depth and com-
plexity of information made available by the PCAWG con-
sortium. Each of the tools presented here was either created or
extended in the context of the PCAWG project to address those
whole-genome visualization challenges.
Nevertheless, we expect that other tools will be developed to
address the visualization challenges associated with the whole-
genome PCAWG data. In fact, another group in the PCAWG
consortium has created an online tool to explore the panorama of
driver mutations in PCAWG tumors. The tool can be found via
Gitools interactive heatmaps18 (http://www.gitools.org/pcawg). We
hope that further visualization and analysis tool development will
be facilitated by the open-source code for the tools described here
(Supplementary Table 1), as well as by embeddable javascript
modules for some tools’ functionalities (Supplementary Table 2).
Reporting summary. Further information on research design is
available in the Nature Research Reporting Summary linked to
this article.
Data availability
Somatic and germline variant calls, mutational signatures, subclonal reconstructions,
transcript abundance, splice calls, and other core data generated by the ICGC/TCGA
Pan-cancer Analysis of Whole Genomes Consortium is described here1 and available for
download at https://dcc.icgc.org/releases/PCAWG. Additional information on accessing
the data, including raw read files, can be found at https://docs.icgc.org/pcawg/data/. In
accordance with the data access policies of the ICGC and TCGA projects, most
molecular, clinical, and specimen data are in an open tier, which does not require access
Fig. 5 PCAWG Central Nervous System meta-cohort donor-driver events in PCAWG-Scout. This Cytoscape-based visualization, available from the Study
report, shows donors as hexagons and genes as circles. The PCAWG (Central Nervous System) CNS meta-cohort consists of the samples from cohorts
identified by the codes CNS-GBM, CNS-Medullo, CNS-Oligo, CNS-PiloAstro. Edges represent driver events that either were validated or were only
predicted by the PCAWG Drivers Working Group; validated driver events are colored green and predicted driver events are colored orange. Most of the
driver events for IDH1 are shown as only predicted, whereas all of those for PTCH1 have been validated. The hexagon border thickness for each donor
corresponds to the reported survival time. The size of each gene circle is proportional to the extent to which mutations found in the cohort for that gene
have damage scores (MetaLR_score from DbNSFP v3.2a) higher than the scores for all possible SNVs that can happen over that gene (one-sided t test; the
sample size varies from gene to gene). Genes IDH1, TP53, and DDX3X stand out as being more damaged than expected by chance. The circle color for each
gene corresponds to its differential expression as calculated by PCAWG-Scout (FDR-corrected two-sided t statistic) when comparing IDH1-mutant samples
with IDH1-wild type tumor samples; purple, light gray, and gold denote underexpression, no significant differential, and overexpression, respectively. The
upper and lower bounds of the coloring gradient are defined on the basis of the entire genome, not just for the genes represented in the graph. IDH1 is
among the most under-expressed, along with FN1 and CHEK2. FN1 and CHEK2 have driver events that co-occur in some samples with those for IDH1. PTCH1
is overexpressed in IDH1 mutants. Graphical esthetics of node border width, node size, node color, and edge color are configurable interactively. Details of
the analysis and instructions for reproducing this visualization are available in Supplementary Note 3.
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approval. To access genetically sensitive information, such as germline alleles and
underlying sequencing data, researchers will need to apply to the TCGA Data Access
Committee (DAC) via dbGaP (https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login)
for access to the TCGA portion of the dataset and to the ICGC Data Access Compliance
Office (DACO; http://icgc.org/daco) for the ICGC portion. In addition, to access somatic
single-nucleotide variants derived from TCGA donors, researchers will also need to
obtain dbGaP authorization. Derived datasets within each tool can be found in
Supplementary Table 3. The source data underlying Figs. 1–5, excepting the controlled
data, are provided as a Source data file. Corresponding authors for respective tools: ICGC
Data Portal, J. Zhang, junjun.zhang@oicr.on.ca; UCSC Xena, J. Zhu, jzhu@soe.ucsc.edu;
Chromothripsis Explorer, P.J.P., peter_park@hms.harvard.edu; Expression Atlas, I.P.,
irenep@ebi.ac.uk; PCAWG-Scout, M.V., miguel.vazquez.g@bsc.es.
Code availability
The core computational pipelines used by the PCAWG Consortium for alignment,
quality control, and variant calling are available to the public at https://dockstore.org/
search?search=pcawg under the GNU General Public License v3.0, which allows for
reuse and distribution. The code for all tools in this paper are open source and publicly
available. Code for the ICGC Data Portal is available at https://github.com/icgc-dcc/dcc-
portal. Code for the UCSC Xena Browser is available at https://github.com/ucscXena/
ucsc-xena-client. Code for the Chromothripsis Explorer is available at https://github.
com/parklab/ShatterSeek. Code for the Expression Atlas is at https://github.com/gxa/
atlas. Code for PCAWG-Scout is at http://mikisvaz.github.io/rbbt/, https://github.com/
Rbbt-Workflows, and https://github.com/Rbbt-Apps/PCAWGScout.
Received: 15 January 2019; Accepted: 19 May 2020;
References
1. Campbell, P. J. et al. Pan-cancer analysis of whole genomes. Nature 578, 82–93
(2020).
2. Kent, W. J. et al. The human genome browser at UCSC. Genome Res. 12,
996–1006 (2002).
3. Zerbino, D. R. et al. Ensembl 2018. Nucleic Acids Res. 46, D754–D761 (2018).
4. Piñeiro-Yáñez, E. et al. PanDrugs: a novel method to prioritize anticancer drug
treatments according to individual genomic data. Genome Med 10, 41 (2018).
5. Shepherd, R. et al. Data mining using the Catalogue of Somatic Mutations in
Cancer BioMart. Database (Oxford) 2011, bar018 (2011).
6. Carithers, L. J. et al. A novel approach to high-quality postmortem tissue
procurement: the GTEx Project. Biopreserv. Biobank 13, 311–317 (2015).
7. Zhang, J. et al. The International Cancer Genome Consortium Data Portal.
Nature Biotechnology 37, 367–369 (2019).
8. Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the
Xena platform. Nat Biotechnol 38, 675–678 (2020).
9. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single
catastrophic event during cancer development. Cell 144, 27–40 (2011).
10. Cortés-Ciriano, I. et al. Comprehensive analysis of chromothripsis in 2,658
human cancers using whole-genome sequencing. Nat. Genet. https://doi.org/
10.1038/s41588-019-0576-7 (2020).
11. Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in
cancer genomes. Cell 152, 1226–1236 (2013).
12. Notta, F. et al. A renewed model of pancreatic cancer evolution based on
genomic rearrangement patterns. Nature 538, 378–382 (2016).
13. Yu, Y., Ouyang, Y. & Yao, W. shinyCircos: an R/Shiny application for
interactive creation of Circos plot. Bioinformatics 34, 1229–1231 (2018).
14. Petryszak, R. et al. Expression Atlas update—an integrated database of gene
and protein expression in humans, animals and plants. Nucleic Acids Research
44, (D1):D746–D752 (2016).
15. Fonseca, N. A., Petryszak, R., Marioni, J. & Brazma, A. iRAP - an integrated
RNA-seq Analysis Pipeline. Preprint at https://doi.org/10.1101/005991 (2014).
16. John, J., Powell, K., Katie Conley-LaComb, M. & Chinni, S. R. TMPRSS2-ERG
fusion gene expression in prostate tumor cells and its clinical and biological
significance in prostate cancer progression. J. Cancer Sci. Ther. 4, 94–101 (2012).
17. Adamo, P. & Ladomery, M. R. The oncogene ERG: a key factor in prostate
cancer. Oncogene 35, 403–414 (2016).
18. Rheinbay, E. et al. Analyses of non-coding somatic drivers in 2,658 cancer
whole genomes. Nature 578, 102–111 (2020).
Acknowledgements
The ICGC Data Portal development is supported by the Ontario Institute for Cancer
Research (OICR) through funding provided by the government of Ontario. UCSC Xena
development is supported by the National Cancer Institute of the National Institutes of
Health under award numbers 5U24CA180951-04 and 5U24CA210974-02. The content is
solely the responsibility of the authors and does not necessarily represent the official views of
the National Institutes of Health. Chromothripsis Explorer development is supported by the
European Union’s Framework Programme For Research and Innovation Horizon 2020
(2014-2020) under the Marie Curie Sklodowska-Curie Grant Agreement No. 703543
(I.C.-C.). Expression Atlas development is supported by the European Molecular Biology
Laboratory (EMBL) member states, the Single Cell Gene Expression Atlas from the Well-
come Trust (grant numbers 108437/Z/15/Z), the National Science Foundation of USA grant
to Gramene database [NSF IOS #1127112], Open Targets, and Chan Zuckerberg Initiative.
PCAWG-Scout development is supported by joint BSC-IRB-CRG Program in Computa-
tional Biology and Severo Ochoa Award SEV 2015-0493. In addition, this work has been
supported by the Spanish Government (SEV 2015-0493) and from the BSC-Lenovo Master
Collaboration Agreement (2015). We acknowledge the contributions of the many clinical
networks across ICGC and TCGA who provided samples and data to the PCAWG Con-
sortium and the contributions of the Technical Working Group and the Germline Working
Group of the PCAWG Consortium for collation, realignment, and harmonized variant
calling of the cancer genomes used in this study. We thank the patients and their families for
their participation in the individual ICGC and TCGA projects.
Author contributions
For the ICGC Data Portal, V.F. and J. Zhang led the development of the portal; J. Zhang
led data model design of Data Repositories, contributed to PCAWG data production,
managed and performed cleansing and migration of PCAWG data; Q.X. performed data
QC, cleansing, and migration of PCAWG data; and B.D.O. contributed to PCAWG data
production. For UCSC Xena, J. Zhu led the system design and data ingestion, B.C. led the
software architecture design and coding, and M.G. led the user interface design, user
outreach, and user support. I.C.-C. designed and implemented the Chromothripsis
Explorer, with input from P.J.P. For Expression Atlas, I.P. led its development and the
integration of PCAWG datasets. For Expression Atlas, N.A.F. performed the data ana-
lysis, R.P. contributed to the integration of the PCAWG data, A.F. curated the PCAWG
data, and M.K. contributed to the curation and analysis of PCAWG data. W.B., E.B., and
A.M.-P. contributed to the development of the web interface for Expression Atlas. E.P.-Y.
produced the PanDrugs annotations used in PCAWG-Scout, with contributions from
F.A.-S. M.V. developed PCAWG-Scout and contributed to several PCAWG working
groups. A.V. contributed to several PCAWG working groups. D.H., W.H., and M.V. led
the PCAWG-12 working group: Exploratory: portals, visualization and software infra-
structure. The manuscript was led by M.V. M.G., J. Zhang, I.P., M.V., I.C.-C., and J. Zhu
contributed to the concept of the manuscript. The manuscript was prepared by M.G.,
J. Zhang, I.P., M.V., I.C.-C., and J. Zhu, with contributions from J.N.W., P.J.P., A.V.,
N.A.F., V.F., and E.P.-Y.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-16785-6.
Correspondence and requests for materials should be addressed to M.J.G.
Peer review information Nature Communications thanks the anonymous reviewer(s) for
their contribution to the peer review of this work.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16785-6 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3400 | https://doi.org/10.1038/s41467-020-16785-6 | www.nature.com/naturecommunications 9
